Practical concept of pharmacokinetics/pharmacodynamics in the management of skin and soft tissue infections

Current Opinion in Infectious Diseases

Volumn 29, Issue 2, 2016, Pages 153-159

  Pea, Federico ^a,b  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

Author keywords

Penetration rate; Pharmacokinetics pharmacodynamics; Probability of target attainment; Severe sepsis

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CEFAZOLIN; CEFTAROLINE FOSAMIL; COTRIMOXAZOLE; DALBAVANCIN; DAPTOMYCIN; DORIPENEM; ERTAPENEM; FLUCLOXACILLIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; ORITAVANCIN; PIPERACILLIN; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEDIZOLID; TIGECYCLINE; VANCOMYCIN;

ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; BACTERICIDAL ACTIVITY; BLISTER; CRITICALLY ILL PATIENT; DIABETIC MICROANGIOPATHY; DIABETIC PATIENT; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MONITORING; DRUG PENETRATION; EFFECTIVE CONCENTRATION; HUMAN; INTENSIVE CARE UNIT; INTERSTITIAL FLUID; MAINTENANCE DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS (TOPIC); MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL CLEARANCE; REVIEW; SEPSIS; SEPTIC SHOCK; SKIN AND SOFT TISSUE INFECTION; SKIN INFECTION; SOFT TISSUE INFECTION; URINARY EXCRETION; DISEASE MANAGEMENT; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS;

ANTI-BACTERIAL AGENTS; DISEASE MANAGEMENT; DRUG MONITORING; HUMANS; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS;

EID: 84959909078     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000256     Document Type: Review

References (47)

1. Stein GE, Wells EM. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant staphylococcus aureus: vancomycin and linezolid. Curr Med Res Opin 2010;26:571-588.
2. Azeredo FJ, Dalla Costa T, Derendorf H. Role of microdialysis in pharmacokinetics and pharmacodynamics: current status and future directions. Clin Pharmacokinet 2014;53:205-212.
3. Marwick C, Broomhall J, McCowan C, et al. Severity assessment of skin and soft tissue infections: cohort study of management and outcomes for hospitalized patients. J Antimicrob Chemother 2011;66:387-397.
4. Sartelli M, Malangoni MA, May AK, et al. World society of emergency surgery (WSES) guidelines for management of skin and soft tissue infections. World J Emerg Surg 2014;9:57.
5. Pea F. Plasma pharmacokinetics of antimicrobial agents in critically ill patients. Curr Clin Pharmacol 2013;8:5-12.
6. Pea F, Viale P. Bench-to-bedside review: appropriate antibiotic therapy in severe sepsis and septic shock - does the dose matter? Crit Care 2009;13:214.
7. Blot SI, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient: concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev 2014;77:3-11.
8. Nemeth J, Oesch G, Kuster SP. Bacteriostatic versus bactericidal antibiotics for patients with serious bacterial infections: systematic review and metaanalysis. J Antimicrob Chemother 2015;70:382-395. An interesting meta-analysis showing that distinguishing between bacteriostatic and bactericidal agents may be clinically irrelevant in treating severe infections.
9. Mortin LI, Li T, Van Praagh AD, et al. Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria. Antimicrob Agents Chemother 2007;51:1787-1794.
10. Tsoulas C, Nathwani D. Review of meta-analyses of vancomycin compared with new treatments for gram-positive skin and soft-tissue infections: are we any clearer? Int J Antimicrob Agents 2015;46:1-7.
11. Kauf TL, McKinnon P, Corey GR, et al. An open-label, pragmatic, randomized controlled clinical trial to evaluate the comparative effectiveness of daptomycin versus vancomycin for the treatment of complicated skin and skin structure infection. BMC Infect Dis 2015;15:503.
12. Hamada Y, Kuti JL, Nicolau DP. Vancomycin serum concentrations do not adequately predict tissue exposure in diabetic patients with mild to moderate limb infections. J Antimicrob Chemother 2015;70:2064-2067. A study showing the importance of measuring tissue exposure in diabetic patients.
13. Laethem T, De Lepeleire I, McCrea J, et al. Tissue penetration by ertapenem, a parenteral carbapenem administered once daily, in suction-induced skin blister fluid in healthy young volunteers. Antimicrob Agents Chemother 2003;47:1439-1442.
14. Bergan T, Engeset A, Olszewski W, et al. Extravascular penetration of highly protein-bound flucloxacillin. Antimicrob Agents Chemother 1986;30:729-732.
15. Maglio D, Teng R, Thyrum PT, et al. Pharmacokinetic profile of meropenem, administered at 500 milligrams every 8 h, in plasma and cantharidin-induced skin blister fluid. Antimicrob Agents Chemother 2003;47:1771-1773.
16. Nicolau DP, Sun HK, Seltzer E, et al. Pharmacokinetics of dalbavancin in plasma and skin blister fluid. J Antimicrob Chemother 2007;60:681-684.
17. Fetterly GJ, Ong CM, Bhavnani SM, et al. Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Antimicrob Agents Chemother 2005;49:148-152.
18. Trampuz A, Wenk M, Rajacic Z, Zimmerli W. Pharmacokinetics and pharmacodynamics of levofloxacin against streptococcus pneumoniae and staphylococcus aureus in human skin blister fluid. Antimicrob Agents Chemother 2000;44:1352-1355.
19. Sun HK, Ong CT, Umer A, et al. Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob Agents Chemother 2005;49:1629-1632.
20. Stein GE, Throckmorton JK, Scharmen AE, et al. Tissue penetration and antimicrobial activity of standard- and high-dose trimethoprim/sulfamethoxazole and linezolid in patients with diabetic foot infection. J Antimicrob Chemother 2013;68:2852-2858.
21. Burkhardt O, Brunner M, Schmidt S, et al. Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis. J Antimicrob Chemother 2006;58:632-636.
22. Sauermann R, Burian B, Burian A, et al. Tissue pharmacokinetics of ertapenem at steady-state in diabetic patients with leg infections. J Antimicrob Chemother 2013;68:895-899.
23. Burian B, Zeitlinger M, Donath O, et al. Penetration of doripenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers. Antimicrob Agents Chemother 2012;56:532-535.
24. Joukhadar C, Frossard M, Mayer BX, et al. Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med 2001;29:385-391.
25. Lorentzen H, Kallehave F, Kolmos HJ, et al. Gentamicin concentrations in human subcutaneous tissue. Antimicrob Agents Chemother 1996;40:1785-1789.
26. Skhirtladze K, Hutschala D, Fleck T, et al. Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery. Antimicrob Agents Chemother 2006;50:1372-1375.
27. Kim A, Suecof LA, Sutherland CA, et al. In vivo microdialysis study of the penetration of daptomycin into soft tissues in diabetic versus healthy volunteers. Antimicrob Agents Chemother 2008;52:3941-3946.
28. Joukhadar C, Dehghanyar P, Traunmuller F, et al. Increase of microcirculatory blood flow enhances penetration of ciprofloxacin into soft tissue. Antimicrob Agents Chemother 2005;49:4149-4153.
29. Bellmann R, Kuchling G, Dehghanyar P, et al. Tissue pharmacokinetics of levofloxacin in human soft tissue infections. Br J Clin Pharmacol 2004;57:563-568.
30. Dehghanyar P, Burger C, Zeitlinger M, et al. Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses. Antimicrob Agents Chemother 2005;49:2367-2371.
31. Traunmuller F, Schintler MV, Spendel S, et al. Linezolid concentrations in infected soft tissue and bone following repetitive doses in diabetic patients with bacterial foot infections. Int J Antimicrob Agents 2010;36:84-86.
32. Wiskirchen DE, Shepard A, Kuti JL, Nicolau DP. Determination of tissue penetration and pharmacokinetics of linezolid in patients with diabetic foot infections using in vivo microdialysis. Antimicrob Agents Chemother 2011;55:4170-4175.
33. Sahre M, Sabarinath S, Grant M, et al. Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers. Int J Antimicrob Agents 2012;40:51-54.
34. Bulik CC, Wiskirchen DE, Shepard A, et al. Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis. Antimicrob Agents Chemother 2010;54:5209-5213.
35. De Waele J, Carlier M, Hoste E, et al. Extended versus bolus infusion of meropenem and piperacillin: a pharmacokinetic analysis. Minerva Anestesiol 2014;80:1302-1309.
36. Pea F, Crapis M, Cojutti P, Bassetti M. Daptomycin underexposure in a young intravenous drug user who was affected by life-threatening Staphylococcus aureus-complicated skin and soft tissue infection associated with bacteraemia. Infection 2014;42:207-210.
37. Pea F, Viale P. The antimicrobial therapy puzzle: could pharmacokineticpharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients? Clin Infect Dis 2006;42:1764-1771.
38. Ray A, Malin D, Nicolau DP, Wiskirchen DE. Antibiotic tissue penetration in diabetic foot infections a review of the microdialysis literature and needs for future research. J Am Podiatr Med Assoc 2015;105:520-531.
39. So W, Kuti JL, Nicolau DP. Population pharmacokinetics of cefazolin in serum and tissue for patients with complicated skin and soft tissue infections (cSSTI). Infect Dis Ther 2014. [Epub ahead of print]
40. Canut A, Isla A, Rodriguez-Gascon A. Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skinstructure infections in patients with normal and impaired renal function. Int J Antimicrob Agents 2015;45:399-405. An interesting study suggesting the possible need for higher than standard dosages of ceftaroline fosamil for optimal treatment of MRSA-related SSTIs.
41. De Waele JJ, Dumoulin A, Janssen A, Hoste EA. Epidemiology of augmented renal clearance in mixed ICU patients. Minerva Anestesiol 2015;81:1079-1085.
42. Hobbs AL, Shea KM, Roberts KM, Daley MJ. Implications of augmented renal clearance on drug dosing in critically ill patients: a focus on antibiotics. Pharmacotherapy 2015;35:1063-1075. An overview on the role of augmented renal clearance in conditioning the need for alternative dosing of antimicrobials in critically ill patients.
43. Sime FB, Udy AA, Roberts JA. Augmented renal clearance in critically ill patients: etiology, definition and implications for beta-lactam dose optimization. Curr Opin Pharmacol 2015;24:1-6.
44. Udy AA, De Waele JJ, Lipman J. Augmented renal clearance and therapeutic monitoring of beta-lactams. Int J Antimicrob Agents 2015;45:331-333. A critical evaluation of the role of TDM in the managhement of therapy with ba-lactams in the critically ill patients.
45. Hites M, Taccone FS, Wolff F, et al. Case-control study of drug monitoring of beta-lactams in obese critically ill patients. Antimicrob Agents Chemother 2013;57:708-715.
46. Pea F, Cojutti P, Sbrojavacca R, et al. TDM-guided therapy with daptomycin and meropenem in a morbidly obese, critically ill patient. Ann Pharmacother 2011;45:e37.
47. Pai MP. Treatment of bacterial infections in obese adult patients: how to appropriately manage antimicrobial dosage. Curr Opin Pharmacol 2015;24:12-17.